Investing.comDoubao · 实盘不做把握 5/10不做原因:风险收益比不佳
北京时间·🕒 发布 18:08:38·⟳ 抓取 18:09:13 +35s·⚡ 决策 10-12 18:11:04 +1m51s·15.3 天前
DataMeds AI子公司Helomics的ChemoFx化疗药敏检测获Humana Medicaid覆盖政策纳入
消息方向正面但实质薄弱：单一支付方的Medicaid（非商业险、非全计划覆盖）准入、政策7月22日即已生效属旧政策新发新闻稿、检测未经FDA批准且无任何销量/收入量化；标的是950万美元市值的低价股，20日波动+229%后连日阴跌、当日-12.94%且盘前微跌，市场对利好不买账，属典型PR驱动投机票，不具备可量化的正期望edge。
📄 原文Investing.com↗ 原文
DataMeds AI subsidiary gains Medicaid coverage for cancer test
By Investing.com Advertisement Advertisement DataMeds AI subsidiary gains Medicaid coverage for cancer test Company New…
不做 DataMeds AI（MEDS.US）
单一支付方Medicaid覆盖、政策7月22日已生效属旧闻新发，无检测量/收入量化，ChemoFx未经FDA批准；标的为950万美元市值高波动低价股（20日+229%后持续回落、日波动约66%），消息当日反跌12.94%、盘前无买盘，风险收益不支持做多；催化强度亦不满足做空红线，故双向回避
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
ChemoFx获Humana Medicaid覆盖是准入层面的边际利好，但仅限单一支付方Medicaid、政策生效已近3个月且无收入指引，无法量化业绩弹性；标的为高波动低价股且利好当日反跌12.94%，无edge，回避。
消息传播链
- 公司2026-10-12早晨发布新闻稿宣布Humana Medicaid覆盖政策，Investing.com等随后转载；政策实际生效日为2026-07-22市场反应:MEDS 10月9日收盘2.96美元（当日-12.94%），10月12日盘前约2.96美元基本持平，利好无正向重定价
关键理由
- 支付方覆盖扩围理论上提升ChemoFx检测可及性，实验室自动化已就绪，是真实但微弱的正面准入进展
主要风险
- 覆盖政策2026-07-22已生效，本次为旧政策新闻稿，且仅限Humana Medicaid特定指征、非全计划覆盖，商业化放量高度不确定
- MEDS为约950万美元市值低价股，20日+229%后剧烈回落（52周高点73美元跌至2.96美元），日波动率约66%，公关驱动炒作与逼空双杀风险高
反向证据
- 做多前查反向 · 来源 web · 影响 weakens
公司为约950万美元市值、负PE的低价股，股价较52周高点73美元跌去96%，20日曾+229%随后连日大跌，10月9日利好环境下仍-12.94%，显示派发/炒作退潮特征；新闻稿未提供任何检测量或收入数据，且检测未经FDA批准
检索:DataMeds AI MEDS stock dilution SEC offering going concern Helomics ChemoFx 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例缺失叠加标的低价高波动属性，支持以证据薄、风险收益差为由回避，而非小仓试探
方向:无足够对齐先例：微型市值LDT诊断公司单一支付方Medicaid覆盖政策的事件缺乏可溯源首发先例面板
涨幅量级:无法用先例校准幅度，不据此设定止盈止损
形态:不可评估
工具执行结果 · 成功 3 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 10 ms
{"result": "search_processed_events:agent query=`datameds ai helomics chemofx humana medicaid coverage | helomics humana pharmacogenomics testing coverage policy | meds chemofx assay medicaid coverage determination`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回 - stock_quote 成功 stock_tools HTTP · 1,765 ms
{ - web_search 成功 doubao_search · 2,186 ms
豆包搜索结果（原始查询:DataMeds AI Helomics ChemoFx Humana Medicaid coverage；API SearchType:web）
原文全文
展开原文 · 7,463 字
DataMeds AI subsidiary gains Medicaid coverage for cancer test By Investing.com
Advertisement
Advertisement
DataMeds AI subsidiary gains Medicaid coverage for cancer test
Company News
Published
Oct 12, 2026, 06:08 AM
DataMeds AI subsidiary gains Medicaid coverage for cancer test
View all comments (0)
0
DataMeds AI subsidiary gains Medicaid coverage for cancer test
View all comments (0)
0
© Reuters
In this article:
MEDS
-12.94%
TAMPA, Fla. -
DataMeds AI
, Inc. (
NASDAQ:MEDS
) announced today that its Helomics Corporation subsidiary received Medicaid coverage determination from Humana for the ChemoFx Assay in gynecologic cancers, according to a press release statement.
The ChemoFx Assay is a chemoresponse test that measures how a patient’s live tumor cells respond to chemotherapy agents. Humana’s Medicaid Coverage Policy Adoption Forum incorporated the test in its Coverage Determination for Pharmacogenomics Testing, effective July 22, 2026.
Under the policy, Humana Medicaid members may be eligible for the ChemoFx Assay, billed under CPT codes 81535 and 81536, for specific indications including rare cancers with no established treatment guidelines, initial biopsy or surgery, recurrent cancer, treatment-refractory cases, or when patients cannot tolerate recommended treatment. The assay is not currently covered under all Humana plans.
Helomics Corporation operates a CLIA-certified clinical laboratory in Pittsburgh, Pennsylvania. The ChemoFx Assay tests a patient’s live tumor cells against a panel of chemotherapy agents. The test has not been cleared or approved by the U.S. Food and Drug Administration.
Gerald E. Commissiong, Interim Co-CEO of DataMeds AI, said the laboratory is positioned to support additional volume as coverage grows. He noted that Helomics previously invested in lab automation to improve commercial readiness.
The company cited a 2015 peer-reviewed publication that estimated mean costs of chemotherapy treatment for recurrent ovarian cancer at $48,758 for empirically treated patients, $33,187 for assay-assisted patients, and $23,986 for assay-adherent patients. The company noted these results may not reflect current treatment patterns or costs.
DataMeds AI is a Tampa-based healthcare company that acquired Helomics Corporation as a subsidiary.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
DataMeds AI subsidiary gains Medicaid coverage for cancer test
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
51,722.60
+67.4
+0.13%
US 500
7,818.90
+7.4
+0.09%
Dow Jones
51,654.95
+423.31
+0.83%
S&P 500
7,811.54
+46.18
+0.59%
Nasdaq
27,366.17
+172.83
+0.64%
S&P 500 VIX
15.48
+0.64
+4.31%
Dollar Index
102.175
+0.153
+0.15%
Crude Oil WTI Futures
92.56
+0.71
+0.77%
Brent Oil Futures
105.56
+0.84
+0.80%
Natural Gas Futures
3.133
-0.087
-2.70%
Gold Futures
4,198.26
-18.04
-0.43%
Silver Futures
60.965
-0.083
-0.14%
Copper Futures
6.7663
+0.0743
+1.11%
US Soybeans Futures
1,283.50
-7.50
-0.58%
U.S. 10Y
5.254
+0.010
+0.19%
U.S. 30Y
5.599
-0.008
-0.14%
U.S. 5Y
5.021
+0.030
+0.60%
U.S. 3M
4.159
+0.008
+0.19%
US 10Y T-Note Futures
104.52
-0.08
-0.07%
Euro Bund Futures
121.04
-0.05
-0.04%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
336.64
-3.78
-1.11%
NVDA
229.28
-1.20
-0.52%
GOOGL
351.66
+3.37
+0.97%
TSLA
382.70
+7.70
+2.05%
AMZN
262.43
+8.37
+3.29%
NFLX
70.30
-1.27
-1.77%
META
718.67
-2.22
-0.31%
Advertisement
Most Popular Articles
News
Analysis
Oil falls, CPI and bank earnings in focus - what’s moving markets
By Investing.co
...
Oct 12, 2026
8 emerging markets to consider in 2027: HSBC
By Investing.co
...
Oct 11, 2026
Shares supported as oil retreats; focus turns to US CPI, earnings
By Reuters
Oct 12, 2026
Premarket movers: Iren jumps on Anthropic deal, CCC surges on buyout talks
By Investing.co
...
Oct 12, 2026
Oil prices fluctuate on Trump’s Russian diesel comments, attacks on Saudi
By Reuters
Oct 12, 2026
Beyond Chips: The 3 Layers of the AI Value Chain
By Ivana Delevs
...
Oct 10, 2026
Sequence of Return Risk: The Math That Breaks Retirements
By Lance Robert
...
Oct 10, 2026
OpenAI’s $20B Revenue Gap: Warning Signs for US Stocks?
By Lee Yang
Oct 09, 2026
Wall Street’s Busy Week: Bank Results, CPI and Retail Sales in Focus
By Ali Merchant
Oct 12, 2026
Treasury Auctions Explained: Why Bond Auctions Matter Even If You Dont Trade Bonds
By Matthew Well
...
Oct 10, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,029.00
-0.66%
19.92M
NVDA
229.28
-0.52%
84.65M
SPCX
162.57
+1.25%
93.04M
TSLA
382.70
+2.05%
38.95M
AAPL
336.64
-1.11%
37.88M
MSFT
535.07
+2.38%
18.50M
AMZN
262.43
+3.29%
34.77M
Name
Last
Chg. %
Vol.
CCI
79.64
+15.60%
14.39M
MRNA
225.00
+14.21%
28.95M
HUM
431.87
+11.56%
4.99M
AMT
182.24
+9.30%
8.51M
SBAC
182.49
+7.34%
2.36M
DDOG
293.26
+7.11%
3.71M
AKAM
106.95
+6.00%
5.80M
Name
Last
Chg. %
Vol.
TMUS
148.58
-13.27%
19.03M
T
22.18
-10.82%
150.53M
VZ
41.65
-10.14%
95.17M
HPQ
30.20
-6.91%
16.70M
FMC
8.35
-6.39%
5.19M
CHTR
103.38
-5.74%
5.11M
FICO
667.58
-5.63%
1.09M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
NVDA
229.28
-0.52%
84.65M
MU
1,029.00
-0.66%
19.92M
SPCX
162.57
+1.25%
93.04M
PLTR
209.05
+5.17%
37.62M
IREN
35.190
-1.46%
38.53M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
Advertisement
Advertisement
DataMeds AI subsidiary gains Medicaid coverage for cancer test
Company News
Published
Oct 12, 2026, 06:08 AM
DataMeds AI subsidiary gains Medicaid coverage for cancer test
View all comments (0)
0
DataMeds AI subsidiary gains Medicaid coverage for cancer test
View all comments (0)
0
© Reuters
In this article:
MEDS
-12.94%
TAMPA, Fla. -
DataMeds AI
, Inc. (
NASDAQ:MEDS
) announced today that its Helomics Corporation subsidiary received Medicaid coverage determination from Humana for the ChemoFx Assay in gynecologic cancers, according to a press release statement.
The ChemoFx Assay is a chemoresponse test that measures how a patient’s live tumor cells respond to chemotherapy agents. Humana’s Medicaid Coverage Policy Adoption Forum incorporated the test in its Coverage Determination for Pharmacogenomics Testing, effective July 22, 2026.
Under the policy, Humana Medicaid members may be eligible for the ChemoFx Assay, billed under CPT codes 81535 and 81536, for specific indications including rare cancers with no established treatment guidelines, initial biopsy or surgery, recurrent cancer, treatment-refractory cases, or when patients cannot tolerate recommended treatment. The assay is not currently covered under all Humana plans.
Helomics Corporation operates a CLIA-certified clinical laboratory in Pittsburgh, Pennsylvania. The ChemoFx Assay tests a patient’s live tumor cells against a panel of chemotherapy agents. The test has not been cleared or approved by the U.S. Food and Drug Administration.
Gerald E. Commissiong, Interim Co-CEO of DataMeds AI, said the laboratory is positioned to support additional volume as coverage grows. He noted that Helomics previously invested in lab automation to improve commercial readiness.
The company cited a 2015 peer-reviewed publication that estimated mean costs of chemotherapy treatment for recurrent ovarian cancer at $48,758 for empirically treated patients, $33,187 for assay-assisted patients, and $23,986 for assay-adherent patients. The company noted these results may not reflect current treatment patterns or costs.
DataMeds AI is a Tampa-based healthcare company that acquired Helomics Corporation as a subsidiary.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
DataMeds AI subsidiary gains Medicaid coverage for cancer test
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
51,722.60
+67.4
+0.13%
US 500
7,818.90
+7.4
+0.09%
Dow Jones
51,654.95
+423.31
+0.83%
S&P 500
7,811.54
+46.18
+0.59%
Nasdaq
27,366.17
+172.83
+0.64%
S&P 500 VIX
15.48
+0.64
+4.31%
Dollar Index
102.175
+0.153
+0.15%
Crude Oil WTI Futures
92.56
+0.71
+0.77%
Brent Oil Futures
105.56
+0.84
+0.80%
Natural Gas Futures
3.133
-0.087
-2.70%
Gold Futures
4,198.26
-18.04
-0.43%
Silver Futures
60.965
-0.083
-0.14%
Copper Futures
6.7663
+0.0743
+1.11%
US Soybeans Futures
1,283.50
-7.50
-0.58%
U.S. 10Y
5.254
+0.010
+0.19%
U.S. 30Y
5.599
-0.008
-0.14%
U.S. 5Y
5.021
+0.030
+0.60%
U.S. 3M
4.159
+0.008
+0.19%
US 10Y T-Note Futures
104.52
-0.08
-0.07%
Euro Bund Futures
121.04
-0.05
-0.04%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
336.64
-3.78
-1.11%
NVDA
229.28
-1.20
-0.52%
GOOGL
351.66
+3.37
+0.97%
TSLA
382.70
+7.70
+2.05%
AMZN
262.43
+8.37
+3.29%
NFLX
70.30
-1.27
-1.77%
META
718.67
-2.22
-0.31%
Advertisement
Most Popular Articles
News
Analysis
Oil falls, CPI and bank earnings in focus - what’s moving markets
By Investing.co
...
Oct 12, 2026
8 emerging markets to consider in 2027: HSBC
By Investing.co
...
Oct 11, 2026
Shares supported as oil retreats; focus turns to US CPI, earnings
By Reuters
Oct 12, 2026
Premarket movers: Iren jumps on Anthropic deal, CCC surges on buyout talks
By Investing.co
...
Oct 12, 2026
Oil prices fluctuate on Trump’s Russian diesel comments, attacks on Saudi
By Reuters
Oct 12, 2026
Beyond Chips: The 3 Layers of the AI Value Chain
By Ivana Delevs
...
Oct 10, 2026
Sequence of Return Risk: The Math That Breaks Retirements
By Lance Robert
...
Oct 10, 2026
OpenAI’s $20B Revenue Gap: Warning Signs for US Stocks?
By Lee Yang
Oct 09, 2026
Wall Street’s Busy Week: Bank Results, CPI and Retail Sales in Focus
By Ali Merchant
Oct 12, 2026
Treasury Auctions Explained: Why Bond Auctions Matter Even If You Dont Trade Bonds
By Matthew Well
...
Oct 10, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,029.00
-0.66%
19.92M
NVDA
229.28
-0.52%
84.65M
SPCX
162.57
+1.25%
93.04M
TSLA
382.70
+2.05%
38.95M
AAPL
336.64
-1.11%
37.88M
MSFT
535.07
+2.38%
18.50M
AMZN
262.43
+3.29%
34.77M
Name
Last
Chg. %
Vol.
CCI
79.64
+15.60%
14.39M
MRNA
225.00
+14.21%
28.95M
HUM
431.87
+11.56%
4.99M
AMT
182.24
+9.30%
8.51M
SBAC
182.49
+7.34%
2.36M
DDOG
293.26
+7.11%
3.71M
AKAM
106.95
+6.00%
5.80M
Name
Last
Chg. %
Vol.
TMUS
148.58
-13.27%
19.03M
T
22.18
-10.82%
150.53M
VZ
41.65
-10.14%
95.17M
HPQ
30.20
-6.91%
16.70M
FMC
8.35
-6.39%
5.19M
CHTR
103.38
-5.74%
5.11M
FICO
667.58
-5.63%
1.09M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
NVDA
229.28
-0.52%
84.65M
MU
1,029.00
-0.66%
19.92M
SPCX
162.57
+1.25%
93.04M
PLTR
209.05
+5.17%
37.62M
IREN
35.190
-1.46%
38.53M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
f713424ba4· 2026-10-12 18:11 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前